FDA 'infectious disease' designation for eravacycline boosts Tetraphase
This article was originally published in Scrip
Executive Summary
Shares of Tetraphase Pharmaceuticals nudged up 5.9% in morning trading on 15 July after the company revealed the firm's lead antibiotic candidate eravacycline had been designated by the US FDA as a qualified infectious disease product (QIDP) – a status that could garner the experimental medicine an additional five years of market exclusivity if approved.